In this week's Pharma Pulse, a senior source denies AstraZeneca and Bristol Myers Squibb are in merger talks, Cleveland Clinic and Arrive AI push drone delivery toward pharma's last mile, Kenco's AI ...

Four pharma experts discuss industry trends in M&A, direct-to-patient sales, patient access and commercial strategy at the H1 midyear mark. Access our complete H1/H2 industry report: Six Months In: A ...

MinuteClinic weight-management visits will drop to $29, aiming to integrate clinical assessment, prescribing, dispensing, and longitudinal support without memberships, mail-order limitations, or inter ...

Pharmaceutical Commerce continues its H1 Review/H2 Outlook series, checking in with industry experts on the forecasts they made earlier this year. This installment features Chip Parkinson, CEO of ...

DeepFabric’s first six agents are running in Kenco’s daily operations, automating bids, audits, and exception handling to free staff for higher-judgment work and faster customer responsiveness.

A compressed 150-day period saw policy and market shifts that outpaced typical formulary-driven timelines and catalyzed ...

Drone-based pharmacy delivery is moving from pilots toward operational integration, requiring reliable patient communication, consistent delivery performance, and interoperability with existing ...

Operational traceability hinges on uninterrupted, interoperable event data after release, as warehouse/enterprise systems and partners must preserve product lineage beyond commissioning and ...

Providers of temperature-controlled packaging, storage, and shipping capabilities for the biopharmaceutical industry are about to face their potentially finest moment. Though they are used to ...

In the August issue of Pharmaceutical Commerce, dive into the vital role of drug wholesalers in today's complex pharma supply chain, along with content spotlighting evolving challenges patients face ...

A composite fragility score integrates supplier redundancy, geographic/sovereign concentration, financial dynamics, and purchasing behavior to identify structurally weak medicines and their ...

Exclusive Japanese commercialization via Alfresa de-risks market entry by leveraging an incumbent wholesaler’s channel reach instead of building local distribution infrastructure. Home Care Delivery ...